Current and historical daily PE Ratio for Can Fite Biofarma Ltd (
) from 2005 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Can Fite Biofarma stock (XTAE:CANF) PE ratio as of Jun 10 2024 is 0.
More Details
Can Fite Biofarma Ltd (XTAE:CANF) PE Ratio (TTM) Chart
Can Fite Biofarma Ltd (XTAE:CANF) PE Ratio (TTM) Historical Data
View and export this data going back to 2005. Start your Free Trial
Total 1250
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Can Fite Biofarma PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-10 | At Loss | 2024-04-08 | At Loss |
| 2024-06-09 | At Loss | 2024-04-04 | At Loss |
| 2024-06-06 | At Loss | 2024-04-03 | At Loss |
| 2024-06-05 | At Loss | 2024-04-02 | At Loss |
| 2024-06-04 | At Loss | 2024-04-01 | At Loss |
| 2024-06-03 | At Loss | 2024-03-31 | At Loss |
| 2024-06-02 | At Loss | 2024-03-28 | At Loss |
| 2024-05-30 | At Loss | 2024-03-27 | At Loss |
| 2024-05-29 | At Loss | 2024-03-26 | At Loss |
| 2024-05-28 | At Loss | 2024-03-25 | At Loss |
| 2024-05-27 | At Loss | 2024-03-24 | At Loss |
| 2024-05-26 | At Loss | 2024-03-21 | At Loss |
| 2024-05-23 | At Loss | 2024-03-20 | At Loss |
| 2024-05-22 | At Loss | 2024-03-19 | At Loss |
| 2024-05-21 | At Loss | 2024-03-18 | At Loss |
| 2024-05-20 | At Loss | 2024-03-17 | At Loss |
| 2024-05-19 | At Loss | 2024-03-14 | At Loss |
| 2024-05-16 | At Loss | 2024-03-13 | At Loss |
| 2024-05-15 | At Loss | 2024-03-12 | At Loss |
| 2024-05-14 | At Loss | 2024-03-11 | At Loss |
| 2024-05-13 | At Loss | 2024-03-10 | At Loss |
| 2024-05-12 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-03 | At Loss |
| 2024-05-05 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-25 | At Loss |
| 2024-04-28 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-19 | At Loss |
| 2024-04-22 | At Loss | 2024-02-18 | At Loss |
| 2024-04-21 | At Loss | 2024-02-15 | At Loss |
| 2024-04-18 | At Loss | 2024-02-14 | At Loss |
| 2024-04-17 | At Loss | 2024-02-13 | At Loss |
| 2024-04-16 | At Loss | 2024-02-12 | At Loss |
| 2024-04-15 | At Loss | 2024-02-11 | At Loss |
| 2024-04-14 | At Loss | 2024-02-08 | At Loss |
| 2024-04-11 | At Loss | 2024-02-07 | At Loss |
| 2024-04-10 | At Loss | 2024-02-06 | At Loss |
| 2024-04-09 | At Loss | 2024-02-05 | At Loss |
Can Fite Biofarma Ltd (XTAE:CANF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Can Fite Biofarma Ltd
ISIN : IL0010944739
Compare
Compare
Traded in other countries / regions
CANF.IsraelCANF.USACF5.Germany IPO Date
2005-10-06Description
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers